SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kung Winston

(Last)

(First)

(Middle)

C/O PMV PHARMACEUTICALS, INC.

8 CLARKE DRIVE, SUITE 3

(Street)

CRANBURY

08512

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/24/2020

3. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	COO, CFO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	02/21/2028	Common Stock	238,635	$3.22	D
Stock Option (right to buy)	⁽²⁾	02/21/2028	Common Stock	237,412	$3.22	I	See footnote⁽³⁾
Stock Option (right to buy)	⁽⁴⁾	03/09/2030	Common Stock	87,462	$3.9	D

Explanation of Responses:

1. Of the 476,047 shares originally subject to the option, 357,035 of such shares (the "Time-Based Portion") shall vest according to the following schedule: one fourth of Time Based Portion vested on November 27, 2018, and one forty-eighth of the Time-Based Portion shall vest each month thereafter. The remaining 119,012 shares subject to the option (the "Milestone-Based Portion") shall vest according to the following schedule: one forty-eighth of the Milestone-Based Portion shall immediately vest upon the first day of trading of the Issuer's shares following completion of the Issuer's initial public offering, and one forty-eighth of the Milestone-Based Portion shall vest each month thereafter. The Reporting Person transferred 237,412 vested options as of September 20, 2020 to the Winston Kung Irrevocable Family Trust, and the remaining options held directly by the Reporting Person continue to vest according to the terms of the option grant.

2. All of the shares subject to the option are vested and immediately exercisable.

3. The shares are held of record by the Winston Kung Irrevocable Family Trust for the benefit of the Reporting Person's immediate family.

4. One forty-eighth of the shares subject to the option vested on April 4, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter.

Remarks:

	/s/ David H. Mack, attorney-in-fact	09/24/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.